Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Imraldi sets pace on German price cuts

Executive Summary

Biogen’s Imraldi (adalimumab) biosimilar has entered the German market with a list price just over 40% lower than the cost of the reference brand, AbbVie’s Humira, according to the association of statutory health insurance doctors for the North Rhine region, the KVNO. And while Amgen’s Amgevita and Sandoz/Hexal’s Hyrimoz currently offer more modest list-price discounts to Humira, the KVNO says both suppliers of adalimumab biosimilars have announced price cuts that will come into effect from 15 November.

You may also be interested in...



Biogen Claims Lead Among Adalimumab Biosimilars In Europe

With quarterly sales up to $36m, Biogen says its Imraldi rival to Humira is the market-leading adalimumab biosimilar in Europe.

Benepali Surge And Imraldi Gains Drive Biogen Biosimilars Past US$500m

With sales climbing by more than two-fifths last year, Biogen expects its biosimilar sales to continue to grow by double digits in 2019, driven by the launch of the Imraldi adalimumab biosimilar in mid-October last year.

Pressure Mounts For German Tender Reforms

Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB001401

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel